Neoplasie a sede primitiva ignota

Clinica Terapeutica

Volumn 150, Issue 4, 1999, Pages 301-306

  Foggi, P ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Immunohistochemical staining; Unknown primary site

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; AGED; ANAMNESIS; ARTICLE; BIOPSY; FEMALE; HUMAN; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; NEOPLASM; PALLIATIVE THERAPY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; SEX FACTORS;

EID: 0033154445     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Stewart JF, Tattersall MH, Woods RL, et al.: Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. Br Med J 1:1530-1533, 1979
2. Greco FA, Hainsworth JD: Cancer of unknown primary site. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, New York, Lippincott-Raven, 1997, pp 2423-2443
3. Raber MN, Abbruzzese JL: Unknown primary. In: Abeloff MD, Armitage JO, Lichter AS Niederhuber JE(eds): Clinical oncology, Churchill Livingstone, 1995, pp 1833-1845 Abbruzzese JL, Abbruzzese MC, Lenzi R, et al.: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13(8): 2094-2103, 1995
4. Raber MN, Abbruzzese JL: Unknown primary. In: Abeloff MD, Armitage JO, Lichter AS Niederhuber JE(eds): Clinical oncology, Churchill Livingstone, 1995, pp 1833-1845 Abbruzzese JL, Abbruzzese MC, Lenzi R, et al.: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13(8): 2094-2103, 1995
5. Mayordomo JL, Guerra JM, Guijarro C, et al.: Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 79: 321-324, 1993
6. Le Chevalier T, Cvitkovic E, Caille P, et al.: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 148: 2035-2039, 1988
7. Van der Gaast A, Verweij J, Planting AST, et al.: Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 13(7): 1720-1725, 1995
8. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 57: 120-124, 1986
9. Abbruzzese JL, Abbruzzese MC, Hess KR, et al.: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12: 1272-1280, 1994
10. Pavlidis N, Kalef Ezra J, Briasoulis E, et al.: Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 22: 162-167, 1994
11. Kole AC, Nieweg OE, Pruim J, et al.: Detection of unknown occult primary tumors using positron emission tomography. Cancer 82(6): 1160-1166, 1998
12. Braams JW, Pruim J, Kole AC, et al.: Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 26 (2): 112-115, 1997
13. Matthews P, Ellis IO: Use of immunochemistry in the diagnosis of metastatic carcinoma. Ann Med 28 (4): 297-300, 1996
14. Mackay B, Ordonez NG: Pathological evaluation of neoplasms with unknown primary tumor site. Semin Oncol 20: 206-228, 1993
15. Hainsworth JD, Wright EP, Johnson DH, et al.: Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 9: 1931-1938, 1991
16. Strojan P, Anicin A: Combined surgery and postoperative radiotherapy for cervical lymph node metastases from unknown primary tumour. Radiother Oncol 49(1): 33-40, 1998
17. Nguyen C, Shenouda G, Black MJ, et al.: Metastatic squamous cell carcinoma to cervical lymph nodes from unknown primary mucosal sites. Head Neck 16: 58-63, 1994
18. Jeremic B, Zivic DJ, Matovic M, et al.: Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 5 (4): 262-265, 1993
19. Ellerbroek N, Holmes F, Singletary E, et al.: Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66: 1461-1467, 1990
20. Whillis D, Brown PW, Rodger A: Adenocarcinoma from an unknown primary presenting in women with axillary mass. Clin Oncol R Coll Radiol : 189-192, 1990
21. Dalrymple JC, Bannatyne P, Russel P, et al.: Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases. Cancer 64: 110-115, 1989
22. Strnad CM, Grosh WW Baxter J, et al.: Peritoneal carcinomatosis of unknown primary site in women. Ann Intern Med 111: 213-217, 1989
23. Ransom DT, Patel SR, Keeney GL, et al.: Papillary serous carcinoma of the peritoneum: a review of 33 cases treated with cisplatin-based chemotherapy. Cancer 66: 1091-1094, 1990
24. Hainsworth JD, Erland JB, Kalman LA, et al.: Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol 15(6): 2385-2393, 1997
25. Hainsworth JD, Johnson DH, Greco FA: Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 109: 364-371, 1988
26. Greco FA, Vaughn WK, Hainsworth JD: Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 104: 547-556, 1986
27. Moertel CG, Reitemeier RJ, Schutt AJ, et al.: Treatment of the patient with adenocarcinoma of unknown origin. Cancer 30: 1469-1472, 1972
28. Falkson CI, Cohen GL: Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 55 (2): 116-121, 1998
29. Warner E, Goel R, Chang J, et al.: A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site. Br J Cancer 77(12): 2376-2380, 1998
30. Briasoulis E, Tsavaris N, Fountzilas, et al.: Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: a Hellenic Cooperative Oncology Group phase II study. Oncology 55(5): 426-430, 1998
31. Greco FA, Hainsworth JD: One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site. Semin Oncol 24(6 suppl 19): S19-101-S19-105, 1997
32. Greco FA, Hainsworth JD: The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Semin Oncol 26: 129-133, 1999 (1 suppl 2)
33. Briasoulis E, Tsokos M, Fountzilas G: Bcl-2 and p53 protein expression in metastatic carcinoma of unknown primary origin : biological and clinical implications. A Hellenic Cooperative Oncology Group study. Anticancer Res 18(3B): 1907-1914, 1998
34. Kastan MB, Onyekwere O, Sidransky D, et al.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
35. Elledge RM, Lee W-H: Life and death by p53. Bio Essays 17: 923-930, 1995
36. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Sem Hematol 34: 9-19, 1997
37. Gumerlock PH: Molecular-clinical correlative studies in Non-Small-Cell Lung Carcinoma, ASCO Educational Book Spring: 374-381, 1999